Online citations, reference lists, and bibliographies.
← Back to Search

HIV Dynamics And T-cell Immunity After Three Structured Treatment Interruptions In Chronic HIV-1 Infection

L. Ruiz, G. Carcelain, J. Martinez-Picado, S. Frost, S. Marfil, R. Paredes, J. Romeu, E. Ferrer, K. Morales-Lopetegi, B. Autran, B. Clotet
Published 2001 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
ObjectiveTo evaluate whether controlled re-exposures to autologous HIV-1 could boost HIV-specific immunity and limit virus replication in patients with chronic HIV-1 infection. Patients and designSubjects with at least 2 years virus suppression during antiretroviral therapy and a CD4 : CD8 ratio > 1 were randomly assigned to interrupt highly active antiretroviral treatment (HAART) three times (n = 12) or to continue their previous HAART (n = 14). ResultsIn 10/12 interrupter patients a rebound of HIV-1 RNA was detected in all three structured treatment interruptions (STI). Plasma virus doubling time was shorter during the first STI than in the second and third STI, corresponding to an average 13% reduction in viral basic reproductive rate. However, the mean time before plasma viral load rose to > 50 copies/ml was significantly shorter in the second and third STI. The average frequency of HIV-specific CD8 T cells in the interrupter patients at the end of the third STI cycle was significantly higher compared with the baseline and the end of the first STI. A substantial increase in HIV-specific CD8 T cell frequencies was found in four interrupter patients, whereas there were no changes in all 14 non-interrupter individuals. A weak p24-specific T helper response developed in 5/12 interrupter patients compared with no response in non-interruptors, but these responses were transient and disappeared rapidly. ConclusionThe increase in the control of viral replication, and positive effects of STI on immune responses in this population should encourage the further development of HIV-specific immune-based therapeutic strategies.
This paper references
10.1128/JVI.67.12.7340-7349.1993
Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus
M. Matloubian (1993)
10.1128/jvi.68.12.8056-8063.1994
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
M. Matloubian (1994)
10.1038/373123A0
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
D. Ho (1995)
10.1038/373117A0
Viral dynamics in human immunodeficiency virus type 1 infection
X. Wei (1995)
10.1126/SCIENCE.277.5322.112
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
B. Autran (1997)
10.1126/SCIENCE.278.5342.1447
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.
E. Rosenberg (1997)
10.1086/515587
Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy.
M. Dalod (1998)
10.1097/00002030-199807000-00005
Impact on the immune system of undetectable plasma HIV‐1 RNA for more than 2 years
A. Arnó (1998)
10.1016/S0140-6736(97)10291-4
Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
T. Li (1998)
10.1016/S0140-6736(05)60532-6
Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease
M. Plana (1998)
10.1086/515591
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
M. Lederman (1998)
Long-lasting recovery in CD4 T-cell function and viral-load AIDS 2001, Vol 15 No 9 F26 reduction after highly active antiretroviral therapy in advanced HIV-1 disease
TS Li (1998)
10.1086/314599
Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.
C. Rinaldo (1999)
10.1097/00002030-199904160-00008
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.
A. Neumann (1999)
10.1086/314837
Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy.
O. Pontesilli (1999)
10.1097/00002030-199907300-00002
Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
F. García (1999)
10.1038/8400
HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
C. Pitcher (1999)
10.1016/S0140-6736(98)08468-2
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study
A. Carr (1999)
10.1073/PNAS.96.26.15109
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.
R. Davey (1999)
10.1056/NEJM199905273402101
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
L. Zhang (1999)
10.1038/8394
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
D. Finzi (1999)
10.1172/JCI7371
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.
G. Ortiz (1999)
10.1056/NEJM199905273402102
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
M. Furtado (1999)
10.1128/JVI.73.1.797-800.1999
Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy
G. Ogg (1999)
10.1056/NEJM199905273402114
Control of HIV despite the discontinuation of antiretroviral therapy.
J. Lisziewicz (1999)
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).
C. Gray (1999)
HIV-1-speci®c immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
GM Ortiz (1999)
10.1097/00002030-200003100-00013
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
L. Ruiz (2000)
10.1086/315381
Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy.
P. Haslett (2000)
10.1073/PNAS.97.7.3382
Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes.
A. Oxenius (2000)
10.1086/315748
Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.
E. Papasavvas (2000)
10.4049/jimmunol.165.3.1692
Dynamics of HIV-Specific CD8+ T Lymphocytes with Changes in Viral Load1
L. Mollet (2000)
10.4049/jimmunol.165.3.1692
Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups.
L. Mollet (2000)
10.1073/PNAS.97.20.10948
Antiretroviral resistance during successful therapy of HIV type 1 infection.
J. Martinez-Picado (2000)
10.1038/35035103
Immune control of HIV-1 after early treatment of acute infection
E. Rosenberg (2000)
10.1038/71577
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
B. Ramratnam (2000)
WinBUGS version 1.2 user manual
DJ Spiegelhalter (2000)
10.1128/JVI.75.1.234-241.2001
Transient Mobilization of Human Immunodeficiency Virus (HIV)-Specific CD4 T-Helper Cells Fails To Control Virus Rebounds during Intermittent Antiretroviral Therapy in Chronic HIV Type 1 Infection
Guislaine Carcelain (2001)



This paper is referenced by
10.1097/QAD.0000000000002113
Clinical trials of antiretroviral treatment interruption in HIV-infected individuals
J. Lau (2019)
10.1016/J.APM.2019.05.024
Global dynamics and cost-effectiveness analysis of HIV pre-exposure prophylaxis and structured treatment interruptions based on a multi-scale model
M. Shen (2019)
10.1093/cid/ciz417
Systematic Review And Meta-Analysis of Treatment Interruptions in HIV-1 Infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials.
M. Stecher (2019)
10.23919/ACC.2019.8815245
Positive Feedback Through Inflammation Creates Bistable Behavior in HIV Tissue Sanctuaries
Aditya Jagarapu (2019)
10.1111/imr.12698
Insight into treatment of HIV infection from viral dynamics models
A. Hill (2018)
10.1007/978-3-319-55849-3_4
Integration of Reaction Kinetics Theory and Gene Expression Programming to Infer Reaction Mechanism
Jason R. White (2017)
10.1016/J.PHYSA.2017.05.005
HIV models for treatment interruption: Adaptation and comparison
Andreas Hillmann (2017)
10.1371/journal.ppat.1005745
Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
M. Pinkevych (2016)
10.1371/journal.ppat.1005679
Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions
A. Hill (2016)
10.1371/journal.ppat.1005000
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
M. Pinkevych (2015)
Recomendations from GESIDA/National AIDS plan on antiretroviral therapy in adult patients infected by the human immunodeficiency virus (October 2004)
J. Iribarren (2015)
10.1109/ACC.2014.6859111
Analysis of HIV-1 compartmental model parameters using Bayesian MCMC estimation
E. F. Cardozo (2014)
10.13130/PAROLIN-DEBORA_PHD2014-02-03
MESSA A PUNTO DI TEST ALTERNATIVI PER LO SCREENING DI POTENZIALI INIBITORI DELLA PROTEASI DI HIV-1
D. Parolin (2014)
10.1111/imr.12083
Immune interventions in HIV infection
G. Carcelain (2013)
10.1097/QAD.0b013e3283635232
Association of early HIV viremia with mortality after HIV-associated lymphoma
S. Gopal (2013)
10.1371/journal.pone.0040198
HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics
Rutao Luo (2012)
10.1371/journal.ppat.1002615
An “Escape Clock” for Estimating the Turnover of SIV DNA in Resting CD4+ T Cells
J. Reece (2012)
10.4161/hv.21616
HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation
G. Goldstein (2012)
10.1109/TBME.2012.2201479
Robust Closed-Loop Minimal Sampling Method for HIV Therapy Switching Strategies
E. F. Cardozo (2012)
10.2165/00003495-200262020-00001
Structured Treatment Interruption in Patients Infected with HIV
R. Gulick (2012)
Estudi de l’evolució de l’envolta del VIH-1 en pacients infectats sotmesos a vacunació terapèutica amb virus autòleg inactivat
Meritxell Guilà Matarin (2011)
10.1109/IEMBS.2011.6089910
Measurement error robustness of a closed-loop minimal sampling method for HIV therapy switching
E. F. Cardozo (2011)
10.1109/ACC.2011.5991281
Approximate-model closed-loop minimal sampling method for HIV viral-load minima detection
R. Zurakowski (2011)
10.1016/J.JPROCONT.2010.11.010
Controlling the Evolution of Resistance.
Rutao Luo (2011)
10.1016/j.eimc.2010.12.004
[National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
(2011)
10.1371/journal.pone.0027047
Optimal Antiviral Switching to Minimize Resistance Risk in HIV Therapy
Rutao Luo (2011)
10.1080/13550280590922838
Human immunodeficiency virus type 1 genetic diversity in the nervous system: Evolutionary epiphenomenon or disease determinant?
G. Marle (2011)
10.1128/JVI.02409-10
The Gut Mucosal Viral Reservoir in HIV-Infected Patients Is Not the Major Source of Rebound Plasma Viremia following Interruption of Highly Active Antiretroviral Therapy
Paula Lerner (2011)
10.1186/1475-925X-10-40
Nonlinear observer output-feedback MPC treatment scheduling for HIV
R. Zurakowski (2011)
10.1109/IEMBS.2011.6090599
Quantitative analysis of viral persistence and transient viral load rebound from HIV clinical data
Rutao Luo (2011)
10.1109/ACC.2010.5530483
Modeling-error robustness of a viral-load preconditioning strategy for HIV treatment switching
Rutao Luo (2010)
10.1186/1742-4690-7-89
Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease
D. Jochmans (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar